All News
NORD-STAR substudy of coagulation and fibrinolytic parameters:
〽️Impairement in eRA
⚡️Biologic parameters restored by ttmt.
Effect seemed ▶️ with Biologic vs. MTX + GCs
❕No adjustment on disease activity #OP0059 #EULAR2022 @RheumNow https://t.co/CJHldOimBn
Aurelie Najm AurelieRheumo ( View Tweet)
🚨 Depression = major comorbidity!
DANBIO register 10000+ patients:
❗️10% prescription antidepressants💊
❗️Cumulative mortality ⬆️ w/ OR>6
❗️Particularly in age group <55
#OP0067 #EULAR2022 @RheumNow https://t.co/le8VWBFjPK
Aurelie Najm AurelieRheumo ( View Tweet)
Silverio-Antonio et al. Predictors of ILD development in MCTD. Older age at diagnosis (OR 1.1) and lymphadenopathy at presentation (OR 19.65)! predictors @RheumNow #EULAR2022 POS0901 https://t.co/IJ8Vcaga8o
Richard Conway RichardPAConway ( View Tweet)
Continue with PJP prophylaxis during the 6 months of induction Rx and until B cells repleted and if prednisone > = 20 mg/day #EULAR2022 AAV reccs @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2022 annual meeting is sponsored in part by Bristol-Myers Squibb. All content is chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Chen et al. Adalimumab biosimilar (Amgevita) in JIA. Not a switch study, these are initiators. Expected efficacy and safety outcomes of adalimumab seen here. Good to see more of these data to try and break down the last barriers to biosimilars @RheumNow #EULAR2022 POS1294 https://t.co/yoM2dIXLDQ
Richard Conway RichardPAConway ( View Tweet)
Do biomarkers correlate with change in disease activity in #PsA? Esp IL17F not so much other IL17s, and IL6, IL23. Ian McInnes ? next steps 🤷♀️ to separate responder and non responder @RheumNow #EULAR2022 OP0024 https://t.co/JMmENRa80t
Janet Pope Janetbirdope ( View Tweet)
Norwich regimen of steroids for GCA @cmukhtyar et al. Bespoke regime starting at 1mg/kg tapered over 100 weeks. Drug-free relapse free survival 82% at 100 weeks, 69% 150 weeks. @RheumNow #EULAR2022 POS0793 https://t.co/b5smCqCkgg
Richard Conway RichardPAConway ( View Tweet)
Have always been fascinated by the idea that some b/tsDMARDs might have effects on pain and fatigue beyond inflammation control.
Baricitinib data in RA before, & now this from guselkumab. Substantial effect on pain beyond SJC/CRP attributable?
POS1030 #EULAR2022 #IL23 @RheumNow https://t.co/fxqIGnlkwU
David Liew drdavidliew ( View Tweet)
Proton Rahman discusses #PsA and #fatigue ⬇️ in #Guselkumab RCTs. 2/3 of fatigue was explained by pt factors - pt global and pain, skin, joints, CRP, function drove the data. Ask pt and treat what is treatable.
#OP0025 @eular @RheumNow https://t.co/x4T6sPEi8o
Janet Pope Janetbirdope ( View Tweet)
Cdn cohort of #PsA and CV events - u risk factors were associated with MACE and NSAIDS ⬆️ risk and TNFi ⬇️risk and poor HAQ⬆️ risk. #OP0030 @RheumNow @eular_org Too small events, lipids often absent and spanning 30+ yrs.
Janet Pope Janetbirdope ( View Tweet)
#EULAR OP0072: SMILE: Self-Management Individualised Learning Environment for RA
😀5 modules, with 3-4 more planned in 2022
😀Learning objectives
😀Plan to target resources to questionnaire
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
Behcet disease:
RCT Topical Tacrolimus for mouth ulcers in 40+pts
↘️VAS 2 wks & 3mo
↘️ Number of ulcers
↘️ Ulcer size and duration
↘️ Ulcer severity score
#OP0046 #EULAR2022 @RheumNow
Aurelie Najm AurelieRheumo ( View Tweet)
SELECT-AXIS 2: RCT UPA 15 mgQD vs. PBO in NRAxSpA
as expected:
↘️disease activity
↘️pain and function
↘️QoL
at 14 wks
no new safety alerts https://t.co/2efpx7Mi6i
Aurelie Najm AurelieRheumo ( View Tweet)
AxSpA and AxPsA 2 sides of the same coin or 2 different diseases? Divergent IL-23i efficacy data seem to suggest the latest.
German GESPIC AxPsA cohort:
*More frequently 🚺
*Less frequently B27+
*20% isolated Ax involvement
@Rheumnow OP0026 #EULAR2022 https://t.co/FZP9nEyG7J
Aurelie Najm AurelieRheumo ( View Tweet)
Long-term canakinumab data in FMF from RELIANCE registry. 63% in remission at month 24. @RheumNow #EULAR2022 OP0042 https://t.co/mEIoAszmZq https://t.co/IvR1cSG4Aq
Links:
Richard Conway RichardPAConway ( View Tweet)
Can be challenging to identify early/impending MAS in AoSD. Ruscitti et al propose a model based on systemic score, ferritin, IFN-γ, and IL-10 with AUC 0.99, sensitivity 100% specificity 95% @RheumNow #EULAR2022 OP0044 https://t.co/bbWkdGCnHP
Links:
Richard Conway RichardPAConway ( View Tweet)
More from the VITAL study Dr Costenbader @karen_kc123 et al. 5 year supplementation followed 2 year follow up. Vit D 2000iu ⬇️incident autoimmune disease 21%. RA, PMR, psoriasis trend towards reduction. No effect omega-3 @RheumNow #EULAR2022 OP0038 https://t.co/kbKqDhtN9z https://t.co/HcFXbweEPm
Links:
Richard Conway RichardPAConway ( View Tweet)
Severe heme relapses are common in #SLE pts w/prior severe heme episodes: ATTIKON SLE cohort 800 pts
👉13% w/severe heme dz: TMA, MAS, plt < 30K, hemolysis hgb < 8
👉heme issues preceded SLE dx in 1/3 of pts
👉>50% pts had severe heme flare
👉0 deaths #EULAR2022 @rheumnow POS0116
TheDaoIndex KDAO2011 ( View Tweet)
Low rates of hypersensitivity reactions (HSR) to #anifrolumab
Pooled data MUSE & TULIP-1/-2 w/1100 pts:
👉1 anaphylaxis (0.15%)
👉12 HSR (3%)
👉43 infusion reaction (9%): N/V/headache
👉most easily treatable w/antihistamine, GCs, acetaminophen
#EULAR2022 POS0708 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)